Hem/Onc Roundup: New Treatments for Multiple Myeloma, Skin Cancer Risk in Young Adults, and more

Socioeconomic Status is Associated with Survival for Patients with Pancreatic Cancer

An analysis of patients with pancreatic cancer showed that lower neighborhood socioeconomic status (SES) is associated with more advanced disease at diagnosis, lower probability of receiving surgery, and worse disease-related survival. Patients with lower SES were less likely to receive surgical resection for pancreatic cancer and had a shorter overall  compared with patients with higher SES.

Socioeconomic Status is Associated with Survival for Patients with Pancreatic Cancer

Recent FDA Approvals for Multiple Myeloma and What to Expect from Treatments in Development

Ankit Kansagra, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center and assistant director of the Outpatient Stem Cell Transplant Program, discusses newly approved multiple myeloma (MM) agents and takes a look at the pipeline for interesting therapeutics that may come to market.

Recent FDA Approvals for Multiple Myeloma and What to Expect from Treatments in Development

Skiing and Sunburn: Skin Cancer Risk Still High in the Winter for College Students

Unlike their class schedule, college students’ risk for skin cancer doesn’t take a holiday during the winter months—and they may not be protecting themselves, according to a study. College students rarely use sunscreen, and their proclivity for tanning beds increases when the temperatures outside drop, the study further found.

Skiing and Sunburn: Skin Cancer Risk Still High in the Winter for College Students

Subcutaneous Daratumumab Regimen Improves PFS in Pre-Treated Myeloma

Data presented at the ASH 2020 Annual Meeting showed that subcutaneous daratumumab plus pomalidomide and dexamethasone significantly reduced risk of disease progression in patients with relapsed/refractory multiple myeloma (RRMM) compared with pomalidomide and dexamethasone alone. Daratumumab is an anti-CD38 antibody approved for the treatment of RRMM. A recently approved subcutaneous formulation has shown a similar safety profile to the intravenous version, with a significant reduction in infection-related reactions and shorter administration time.

Subcutaneous Daratumumab Regimen Improves PFS in Pre-Treated Myeloma